Undervalued Drug Manufacturer Stocks on NAS August 2025

August 02, 2025

Drug Manufacturers

Drug Manufacturers are engaged in pharmaceutical manufacturing or sale of a diverse line of drug and healthcare products. This industry group also includes companies engaged in the development and discovery of new dugs, and tobacco and cannabis companies.

NASDAQ

The National Association of Securities Dealers Automated Quotations (Nasdaq) located in New York City, is the most active stock exchange by volume in the United States.

Our Valuation

A stock is considered undervalued if it trades at a discount to our valuation. To determine a stock’s intrinsic value, we developed an algorithm that uses 6 valuation models to determine the value of a company.* To learn more about stockcalc’s valuation methods, click here.

Undervalued Drug Manufacturers stocks

Stocks in this category are held primarily for potential income and capital appreciation.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

SymbolNameClose Price ($)Valuation ($)Difference (%)Average Vol (30D)Market Cap ($M)Yield (%)P/E Ratio
LNTH Lantheus Holdings 75.53 110.27 46.00 1497578 5397 0.00 21.5
GRFS Grifols 8.30 10.66 28.39 752316 5643 0.00 32.1
VTRS Viatris 8.78 11.00 25.28 17392695 10469 5.47 0.0
HCM HUTCHMED (China) 13.90 17.28 24.29 64725 2427 0.00 69.5
AZN AstraZeneca 72.80 85.93 18.04 4993988 227282 2.13 29.3
ALVO Alvotech 11.46 13.14 14.66 283432 3591 0.00 31.0
SNY Sanofi 49.37 54.92 11.24 2329049 121835 4.48 17.6
UTHR United Therapeutics 318.40 350.28 10.01 474327 15474 0.00 12.7
BIIB Biogen 129.79 141.41 8.95 1769557 19027 0.00 12.8
GILD Gilead Sciences 110.08 119.00 8.11 8727872 138591 2.82 23.1
All data provided as at market close May 29, 2025.

Company Details

Lantheus Holdings

LNTH:NAS

Close Price

75.53

Our Valuation

110.27

% Difference

46.00

Market Cap ($M)

5397

P/E Ratio

21.5

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer.

Access the stockcalc valuation


Grifols

GRFS:NAS

Close Price

8.30

Our Valuation

10.66

% Difference

28.39

Market Cap ($M)

5643

P/E Ratio

32.1

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value.

Access the stockcalc valuation


Viatris

VTRS:NAS

Close Price

8.78

Our Valuation

11.00

% Difference

25.28

Market Cap ($M)

10469

P/E Ratio

0.0

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales.

Access the stockcalc valuation


HUTCHMED (China)

HCM:NAS

Close Price

13.90

Our Valuation

17.28

% Difference

24.29

Market Cap ($M)

2427

P/E Ratio

69.5

HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.

Access the stockcalc valuation


Access our valuation for these companies and 9,000+ more

Try the stockcalc platform free for 30 days

Sign Up

AstraZeneca

AZN:NAS

Close Price

72.80

Our Valuation

85.93

% Difference

18.04

Market Cap ($M)

227282

P/E Ratio

29.3

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.

Access the stockcalc valuation


Alvotech

ALVO:NAS

Close Price

11.46

Our Valuation

13.14

% Difference

14.66

Market Cap ($M)

3591

P/E Ratio

31.0

Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.

Access the stockcalc valuation


Sanofi

SNY:NAS

Close Price

49.37

Our Valuation

54.92

% Difference

11.24

Market Cap ($M)

121835

P/E Ratio

17.6

Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron.

Access the stockcalc valuation


United Therapeutics

UTHR:NAS

Close Price

318.40

Our Valuation

350.28

% Difference

10.01

Market Cap ($M)

15474

P/E Ratio

12.7

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil.

Access the stockcalc valuation


Biogen

BIIB:NAS

Close Price

129.79

Our Valuation

141.41

% Difference

8.95

Market Cap ($M)

19027

P/E Ratio

12.8

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity.

Access the stockcalc valuation


Gilead Sciences

GILD:NAS

Close Price

110.08

Our Valuation

119.00

% Difference

8.11

Market Cap ($M)

138591

P/E Ratio

23.1

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care.

Access the stockcalc valuation


Access thousands of valuation reports

Try the stockcalc platform for 30 days for unlimited access to our valuation reports

Sign Up
Lantheus Holdings and Grifols are the most undervalued Drug Manufacturers stocks on the NAS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-drug-manufacturer-stocks-nas-august-2025
Lantheus Holdings $LNTH and Grifols $GRFS are the most undervalued Drug Manufacturers stocks on the #NAS. See the full list: https://www.stockcalc.com/Blog/undervalued-drug-manufacturer-stocks-nas-august-2025
Lantheus Holdings and Grifols are the most undervalued Drug Manufacturers stocks on the NAS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-drug-manufacturer-stocks-nas-august-2025

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.